Article citationsMore>>

T. Trarbach, M. Moehler, V. Heinemann, C. H. Kohne, M. Przyborek, C. Schulz, V. Sneller, G. Gallant and S. Kanzler, “Phase II Trial of Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets and Activates the Tumour Necrosis Factor Apoptosis-Inducing Ligand Receptor-1 (TRAIL-R1), in Patients with Refractory Colorectal Cancer,” British Journal of Cancer, Vol. 102, No. 3, 2010, pp. 506-512. http://dx.doi.org/10.1038/sj.bjc.6605507

has been cited by the following article:

Follow SCIRP
Twitter Facebook Linkedin Weibo
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top